However, our results still raise concerns about the judicious evaluation of Fc-enhanced anti-CTLA-4 antibodies in patients,66 and we believe that they should be exclusively administered in combination with PD-1 blockade to avoid potential deleterious effects in the tumor microenvironment and ensure maximal therapeutic efficacy. This evidence concerns the gene CTLA4 and neoplasm.